Company Filing History:
Years Active: 2004-2007
Title: Keigo Nagao: Innovator in Sustained-Release Preparations
Introduction
Keigo Nagao is a prominent inventor based in Kawanishi, Japan. He has made significant contributions to the field of pharmaceutical preparations, particularly in the development of sustained-release formulations. With a total of 3 patents to his name, Nagao's work has the potential to enhance drug delivery systems.
Latest Patents
Nagao's latest patents include innovative methods for creating sustained-release preparations. One of his notable inventions is a sustained-release preparation that comprises a drug-containing core substance and a multilayered coating layer. This coating layer features adjacent layers containing different hydrophobic organic compound-water-soluble polymer mixtures. The method involves spray-coating a solution onto the core substance and repeating the process with different mixtures to achieve the desired multilayered structure. Another significant patent focuses on the preparation of drug-containing spherical fine particles. This method aims to produce easily-swallowed, controlled-release preparations by utilizing a binder solution and excipient powder to create spherical fine particles with a mean size of 60-200 micrometers.
Career Highlights
Keigo Nagao is associated with Tanabe Seiyaku Company, Limited, where he continues to innovate in the pharmaceutical industry. His work is characterized by a commitment to improving drug formulations and enhancing patient compliance through better delivery systems.
Collaborations
Nagao has collaborated with notable coworkers, including Takashi Ishibashi and Kengo Ikegami. Their combined expertise contributes to the advancement of pharmaceutical technologies and the development of effective drug delivery systems.
Conclusion
Keigo Nagao's contributions to sustained-release preparations reflect his dedication to innovation in the pharmaceutical field. His patents demonstrate a clear focus on improving drug delivery methods, which can significantly benefit patients.